by Administrators Qynapse | Nov 24, 2020 | News
Paris, FRANCE and Boston, MA, November 24, 2020 / PRNewswire / – QYNAPSE Inc. a medical technology company commercializing the most advanced artificial intelligence neuroimaging platform, is pleased to sponsor the 106th Radiology Society of North America (RSNA) Annual...
by Administrators Qynapse | Nov 12, 2020 | News
Paris, France and Boston, MA, November 12th, 2020 – QYNAPSE SAS, a medical technology company commercializing the most advanced neuroimaging AI platform, appoints Matt Ullum, CPA, MBA as Chief Commercial Officer. In his new role, Matt assumes overall responsibility...
by Administrators Qynapse | Nov 3, 2020 | News
Paris, France and Boston, MA, November 3rd, 2020 – QYNAPSE SAS, a medical technology company, will present results on QyPredict®, an AI prediction technology for patient selection in Alzheimer’s clinical trials, at the 13th Clinical Trials on Alzheimer’s Disease...
by Administrators Qynapse | Oct 13, 2020 | News
Acquisition of TRUE POSITIVE MEDICAL DEVICES by QYNAPSE • A strategic collaboration that covers 15 patents, including 9 issued in the U.S. and Canada • A unique technology alliance to improve clinical trials performance and personalize brain diseases management PARIS,...
by Administrators Qynapse | Sep 21, 2020 | News
Worldwide, 50 million people are living with Alzheimer’s and other dementias. By the year 2050, this number could grow to 100 million (1,2). This year, as the world faces the global COVID-19 health crisis, fragile people and especially patients suffering from...
by Administrators Qynapse | Sep 16, 2020 | News
Magnetic Resonance Imaging (MRI) of the brain plays a crucial role in the clinical assessment of Multiple Sclerosis (MS). The analysis of MRI markers is a key component for the disease diagnosis – and these markers are also employed to assess the disease stage,...
